The Emerging Translational Landscape for EPZ-6438, A Small Molecule Inhibitor of EZH2Wednesday, 27 January 2016 at 09:30 Add to Calendar ▼2016-01-27 09:30:002016-01-27 10:30:00Europe/LondonThe Emerging Translational Landscape for EPZ-6438, A Small Molecule Inhibitor of EZH2Epigenetics in Drug Discovery in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com Tazemetostat (EPZ-6438) is a small molecule inhibitor of EZH2 developed by Epizyme that is currently in early clinical development for the treatment of various cancer types. In this talk, the preclinical properties, emerging oncology landscape, and early clinical experience with tazemetostat will be discussed. |